sonesitatug vedotin

Sonesitatug vedotin is a first-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), a tight junction protein aberrantly expressed in certain gastrointestinal cancers, notably **gastric and gastroesophageal junction adenocarcinoma**. The ADC consists of a humanized monoclonal antibody specific for CLDN18.2 linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a cleavable linker. Upon binding to CLDN18.2 on tumor cells, the conjugate is internalized and MMAE is released, resulting in microtubule inhibition and cell death. The drug is being developed primarily for patients with advanced or metastatic gastric and gastroesophageal junction adenocarcinoma expressing CLDN18.2[5][3]. It is currently in phase 3 clinical trials and has been granted Breakthrough Therapy, Fast Track, and Orphan Drug designations in the US and China[5].

Other names

sonesitatug vedotinAZD0901AZD-0901AZD 0901CMG901CMG-901CMG 901